Abstract 2049
Background
Resistance to chemo-radiation therapy is a substantial obstacle compromising treatment of advanced cervical cancer. We investigated if proteomic panel associated with radioresistance can predict the survival in locally advanced cervical cancer.
Methods
One hundred and eighty-one frozen tissue samples were prospectively obtained from patients with locally advanced cervical cancer before chemoradiation. To develop survival prediction model, expression of 22 total and phosphorylated proteins was evaluated by well-based reverse phase protein arrays. and selected proteins were validated by western blotting analysis and immunohistochemistry. The performance of models was internally and externally validated.
Results
Unsupervised clustering stratified patients into three major groups with different overall survival (OS, p = 0.001) and progression-free survival (PFS, p = 0.003) based on detection of BCL2, HER2, CD133, CAIX and ERCC1. reverse-phase protein array results significantly correlated with western blotting results (R2=0.856). The C-index of model was higher than clinical model in the prediction of OS (C-index of 0.86, and 0.62, respectively), and also in the prediction of PFS (C-index of 0.82, and 0.64, respectively). The Kaplan-Meier survival curve shows the dose-dependent prognostic significance of the risk score for PFS and OS. The multivariable Cox proportional hazard model confirmed that the risk score was an independent predictor of PFS (HR, 1.6; 95% CI, 1.4–1.9; p < 0.001) and OS (HR, 2.1; 95% CI, 1.7–2.5; p < 0.001).
Conclusions
A proteomic panel of BCL2, HER2, CD133, CAIX and ERCC1 independently predicted survival in locally advanced cervical cancer patients. This prediction model can help identify chemoradiation responsive tumors, and improve clinical outcome prediction in cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chel Hun Choi.
Funding
Samsung Medical Center.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract